Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced interim data from its multi-center, open-label Phase 2a clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients hospitalized for acute heart failure.

-- Statistically significant reduction in pulmonary capillary wedge

pressure

-- Statistically significant increase in diuresis

-- Trend toward reduction in right atrial pressure

-- Trend toward increase in cardiac output

-- No hypotension

-- No change in serum creatinine

About the Study

The objective of the Phase 2a study is to assess hemodynamic and renal effects of CD-NP in patients with acute heart failure. In this dose escalation trial, stabilized acute heart failure patients receiving standard-of-care heart failure medications were administered an 8-hour infusion of CD-NP at 3 ng/kg/min (n=11), followed by a 14-hour washout period, and then an 8-hour infusion of CD-NP at 10 ng/kg/min (n=9).

Effects on Hemodynamics

Results from the first cohort of patients show a statistically significant reduction in pulmonary capillary wedge pressure (PCWP). Infusion with 3 ng/kg/min of CD-NP resulted in a statistically significant reduction of 2.9 mmHg relative to baseline at eight hours (p=0.02). Infusion of 10 ng/kg/min CD-NP following a washout period resulted in a further reduction of PCWP, which reached statistical significance at two hours after initiation (p=0.02). In patients who completed both doses of CD-NP, there was a statistically significant overall reduction in PCWP of 5.4 mmHg (p=0.002) from the initial baseline PCWP of 23.7 mmHg. The interim results also include an observed tre
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... According to a new market report ... Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled ... Growth, Trends and Forecast, 2013 – 2019,”the global agricultural ... 2012 and is expected to reach USD 28,694.1 million ... 2013 to 2019. , Demand for food production ...
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, ... sciences company with interests in the natural wellness sector ... announced today that its products will be featured at ... Capital Partners, 27 th Annual Growth Stock Conference ... located at 1 Ritz Carlton Drive, Dana ...
(Date:2/26/2015)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... Cowen 35 th Annual Health Care Conference on Tuesday, ... Boston .  Lexicon management will provide an overview of ... of the presentation will be available through Lexicon,s website at ... be available at www.lexpharma.com until April 3, 2015. ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... intended to support renewed strategic transaction,effort, SOUTH ... Bulletin Board: VXGN), a biopharmaceutical company, today announced,the ... of Directors, and the,resignations of three of its ... Stefano, J.D., a principal with the law firm ...
... Health Agency,s Community Health Surveillance System Detects ... ... the course of two hours,on a recent Friday, 20 people arrived, ... Each separately complained of various,gastrointestinal symptoms, including nausea and diarrhea., ...
... Corporation announced today the,commercial release of its Extended ... This technology breaks through classical depth of field,limitations ... of the ImageStream system and enabling new applications,including ... EDF option can be installed at time of ...
Cached Biology Technology:VaxGen Restructures Board of Directors 2E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System 2
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... team has discovered an influenza detector gene that could ... Katharine Magor, a U of A associate professor ... ducks to live, unharmed, as the host of influenza. ... geneI, or RIG-I, enables a duck,s immune system to ...
... Md. -- Amphibiansfrogs, toads, salamanders, and newtsare disappearing worldwide, ... to be stable. This region is home to the ... 70 species reside here), and scientists want to understand ... In research published in the March 29, 2010 issue ...
... the UK and USA announce plans to promote scientific ... The Biotechnology and Biological Sciences Research Council (BBSRC) ... to hold an intensive week long facilitated workshop ... to bring together leading researchers across all disciplines to ...
Cached Biology News:Young salamanders' movement over land helps stabilize populations 2Young salamanders' movement over land helps stabilize populations 3BBSRC and NSF join together to promote new ideas to enhance photosynthesis 2
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Biology Products: